Related references
Note: Only part of the references are listed.Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
J. -F. Yale et al.
DIABETES OBESITY & METABOLISM (2014)
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
Donald E. Kohan et al.
KIDNEY INTERNATIONAL (2014)
The perils of clinical trials
Richard E. Gilbert
KIDNEY INTERNATIONAL (2014)
Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice
Muralikrishna Gangadharan Komala et al.
PLOS ONE (2014)
Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes A Systematic Review and Meta-analysis
Despoina Vasilakou et al.
ANNALS OF INTERNAL MEDICINE (2013)
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
J-F Yale et al.
DIABETES OBESITY & METABOLISM (2013)
Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells-Renoprotection in Diabetic Nephropathy?
Usha Panchapakesan et al.
PLOS ONE (2013)
Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus
Volker Vallon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2013)
Effects of a New SGLT2 Inhibitor, Luseogliflozin, on Diabetic Nephropathy in T2DN Rats
Naoki Kojima et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
Scott C. Thomson et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2012)
A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials
Giovanni Musso et al.
ANNALS OF MEDICINE (2012)
FDA rejects novel diabetes drug over safety fears
Talha Khan Burki
LANCET (2012)
Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area
Gabriel Coll-de-Tuero et al.
BMC NEPHROLOGY (2012)
Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
Christine Clar et al.
BMJ OPEN (2012)
IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
David R. Whiting et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Muhammad A. Abdul-Ghani et al.
ENDOCRINE REVIEWS (2011)
SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
Volker Vallon et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Effect of kidney disease on glucose handling (including genetic defects)
Joaquim Calado et al.
KIDNEY INTERNATIONAL (2011)
Biology of Human Sodium Glucose Transporters
Ernest M. Wright et al.
PHYSIOLOGICAL REVIEWS (2011)
Antidiabetic Medication Use and Prevalence of Chronic Kidney Disease Among Patients With Type 2 Diabetes Mellitus in the United States
Carol E. Koro et al.
CLINICAL THERAPEUTICS (2009)
Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion
Joaquim Calado et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2008)
End-stage renal disease in the United States: An update from the United States renal data system
Robert N. Foley et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Weight loss and the renin-angiotensin-aldosterone system
S Engeli et al.
HYPERTENSION (2005)